Company To Focus Sales On Three Countries

BioMarin Restricts Hemophilia Therapy Sales Amid Slow Sales

Company To Focus Sales On Three Countries

Balancing Act: BioMarin Weighs Roctavian's Future

BioMarin Pharmaceutical announced on Monday that it will limit the sales of its hemophilia gene therapy, Roctavian, to three countries in an effort to overcome slow sales. This decision comes after BioMarin previously considered divesting Roctavian but ultimately decided to retain it.

In a recent update, BioMarin outlined three factors for a more successful launch of Roctavian. However, the company has now discontinued the development of BMN 293, a gene therapy for severe hemophilia B. The move suggests that BioMarin is adjusting its strategy for Roctavian and seeking to streamline its operations.